Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clearside Biomedical ( (CLSD) ) just unveiled an update.
On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.
The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.
Spark’s Take on CLSD Stock
According to Spark, TipRanks’ AI Analyst, CLSD is a Neutral.
Clearside Biomedical’s overall stock score is primarily impacted by its weak financial performance and valuation concerns. While there are positive developments in clinical trials and partnerships, the financial instability and requirement for additional funding weigh heavily on the score. Technical analysis also suggests a lack of strong momentum, contributing to the low score.
To see Spark’s full report on CLSD stock, click here.
More about Clearside Biomedical
Average Trading Volume: 177,044
Technical Sentiment Signal: Sell
Current Market Cap: $60.61M
See more data about CLSD stock on TipRanks’ Stock Analysis page.